Age-related macular degeneration is the leading cause of severe vision loss in adults over fifty in developed countries. That statistic gets cited often enough that it has lost its edge for most people. It shouldn’t. AMD in its advanced form means losing the ability to read, recognize faces, and see fine detail — the central, high-resolution vision that allows most of the activities that make daily life meaningful.
What makes AMD particularly worth understanding is that it’s not a single switch that flips. It’s a condition that develops over decades, driven by a combination of genetic predispositions and modifiable lifestyle factors. The genetic part is not negotiable. The modifiable part represents a meaningful opportunity that most people at risk never fully take advantage of — often because they don’t know they’re at risk, or don’t understand what the levers actually are.
Contents
Fixed Risk Factors: What You Can’t Change
Age is the dominant risk factor for AMD, and it’s not subtle. The condition is rare before fifty, present in early form in a significant minority of people in their sixties, and increasingly prevalent through the seventies and eighties. If you’re fifty or older, AMD risk is part of your health picture whether you’ve thought about it or not.
Genetics play a substantial role. Variants in several genes — most importantly CFH (complement factor H) and ARMS2/HTRA1 — are strongly associated with AMD risk. A family history of AMD meaningfully elevates your own risk. If a parent or sibling has had AMD, your probability of developing it is significantly higher than population average, and your monitoring and prevention strategy should reflect that.
Race and ethnicity also factor in. AMD is more prevalent in people of European ancestry than in those of African or Hispanic ancestry, for reasons that aren’t fully understood but appear to involve both genetic and pigmentation factors. People with lighter-colored irises — which provide less protection against light reaching the retina — have higher AMD rates than those with darker eyes.
Gender is another non-modifiable factor. Women have higher lifetime AMD prevalence than men, partly due to longer life expectancy and partly due to factors that remain under investigation including hormonal influences.
Modifiable Risk Factors: Where Your Choices Matter
The modifiable risk factors for AMD are well-established and worth taking seriously. Several of them are the same factors that show up on every cardiovascular risk list, which is not coincidental — the retina is exquisitely vascular tissue, and what damages blood vessels systemically tends to damage retinal microvasculature specifically.
Smoking
Smoking is the single most powerful modifiable risk factor for AMD, and the effect size is large. Current smokers have roughly double to triple the AMD risk of non-smokers. Former smokers retain elevated risk for years after quitting, though risk does decrease over time. The mechanism involves a combination of oxidative damage — cigarette smoke generates enormous quantities of free radicals that overwhelm retinal antioxidant defenses — and vascular damage to the choroidal blood supply that feeds the macula.
If there’s one lifestyle change that does more for AMD risk reduction than any other, it’s not smoking or stopping if you do. Everything else on this list, while meaningful, operates in a smaller risk range.
Cardiovascular Risk Factors
Hypertension, high cholesterol, and cardiovascular disease are independently associated with increased AMD risk. The choroid — the vascular layer behind the retina that supplies nutrients and oxygen to photoreceptors — is affected by the same atherosclerotic processes that affect coronary arteries. Drusen, the small yellow deposits beneath the retina that characterize early AMD, share compositional similarities with atherosclerotic plaques.
Managing blood pressure and cholesterol through diet, exercise, and medication when indicated is AMD prevention as much as it is heart disease prevention. These aren’t separate health conversations.
Obesity and Sedentary Behavior
Obesity, particularly abdominal obesity, is associated with higher AMD risk and faster progression. The mechanisms likely involve chronic systemic inflammation, which plays a central role in AMD pathogenesis, as well as the vascular effects of metabolic syndrome. Physical activity appears protective, with more active individuals showing lower AMD rates in observational studies — a finding robust enough across multiple populations to be taken seriously.
UV and High-Energy Light Exposure
Cumulative exposure to UV and high-energy visible (blue) light contributes to oxidative damage in the retinal pigment epithelium cells that support photoreceptor health. While the evidence for light exposure as a primary AMD driver is less definitive than smoking or genetics, the plausible mechanism and the ease of the intervention make UV protection worth incorporating consistently. Quality sunglasses that block UVA and UVB, worn during outdoor activities over a lifetime, reduce this cumulative burden.
Nutrition: The Modifiable Factor With the Strongest Evidence
The nutritional epidemiology of AMD is more robust than most chronic disease nutrition research. The Age-Related Eye Disease Studies (AREDS and AREDS2) were landmark randomized controlled trials that demonstrated specific nutritional interventions can significantly reduce the risk of progression from intermediate to advanced AMD.
The AREDS2 formulation — vitamin C, vitamin E, lutein, zeaxanthin, and zinc — reduced progression risk by roughly 25% in people with intermediate AMD or advanced AMD in one eye. Lutein and zeaxanthin replaced beta-carotene in the updated formulation after evidence emerged that high-dose beta-carotene increased lung cancer risk in smokers.
Dietary patterns matter as well. The Mediterranean diet, with its high intake of leafy vegetables, fish, olive oil, and fruit, is consistently associated with lower AMD risk in observational studies. The same foods that provide lutein and zeaxanthin for macular pigment also provide omega-3 fatty acids (from fish), polyphenols, and multiple antioxidant nutrients that support retinal health through overlapping mechanisms.
Macular pigment optical density — the measurable concentration of lutein and zeaxanthin in the macula — is now recognized as a biomarker for AMD risk and protective nutritional status. The article on macular pigment optical density and how it’s measured covers MPOD testing and what your numbers mean in detail.
Glycemic Index and AMD Risk
One less widely known nutritional risk factor is dietary glycemic index. Diets high in refined carbohydrates and added sugars are associated with higher AMD risk in multiple large cohort studies. The mechanism appears to involve advanced glycation end-products (AGEs) that accumulate in retinal tissues and contribute to the drusen formation that characterizes early AMD. Switching from high-glycemic to lower-glycemic carbohydrate sources is a diet modification with AMD-specific benefit, separate from the general metabolic benefits of reducing sugar intake.
Detection and Monitoring: The Role of Regular Exams
Because early AMD produces no symptoms and intermediate AMD may produce only subtle changes that are easy to attribute to normal aging, regular comprehensive eye exams are essential for anyone with risk factors. Dilated retinal examination allows the ophthalmologist or optometrist to see drusen, pigment changes, and other early AMD signs that are invisible to self-assessment.
The Amsler grid — a simple grid of lines with a central dot — is a useful home monitoring tool for people with known early or intermediate AMD. Distortion of the lines or a central blind spot warrants prompt evaluation, as these can indicate progression to the wet (neovascular) form of AMD, which can be treated effectively if caught early.
Note: If you have a family history of macular degeneration, are a smoker or former smoker, or have noticed any distortion of central vision or difficulty reading, please see an eye care professional. Early AMD is asymptomatic and only detectable through examination.
The Asymmetry of Prevention and Treatment
This is worth sitting with: advanced AMD currently has no treatment capable of restoring lost central vision. Wet AMD can be treated to slow or stop progression. Dry AMD, which accounts for the majority of cases, has no approved treatment for the early or intermediate stages, though this is an active area of research. Prevention and early intervention are not just preferable to advanced treatment — they may be the only meaningful options available for decades to come.
That asymmetry makes the modifiable risk factors described here worth acting on now, regardless of whether you currently have any AMD signs. For those interested in a well-formulated nutritional foundation for macular health, the Performance Lab Vision review examines how targeted supplementation aligns with the current evidence base.
